Enterome is a clinical stage company developing off-the-shelf, transformational cancer treatments targeting all tumor types. Ongoing Phase 2 trials for our most advanced program EO2401 have shown promising efficacy in recurrent glioblastoma and adrenal malignancies and good safety in more than 150 patients.
Enterome’s OncoMimics™ approach generates a powerful, long-lasting immune response from the patient’s own effector memory T-cells, overcoming the immune tolerance to self-antigens.
With 5 clinical immune-oncology projects to date, our fully integrated R&D platform has the potential to deliver multiple candidates with a rapid progression “from bench to bedside”. In addition to OncoMimics™ programs, Enterome has also established a partnership with Nestlé Health Science in inflammatory diseases and food allergy.
Enterome’s OncoMimics™ approach generates a powerful, long-lasting immune response from the patient’s own effector memory T-cells, overcoming the immune tolerance to self-antigens.
With 5 clinical immune-oncology projects to date, our fully integrated R&D platform has the potential to deliver multiple candidates with a rapid progression “from bench to bedside”. In addition to OncoMimics™ programs, Enterome has also established a partnership with Nestlé Health Science in inflammatory diseases and food allergy.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Ile de France
Company HQ Country:
France
Year Founded:
2012
Main Therapeutic Focus:
Oncology
Lead Product in Development:
EO2401
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
